Related Experiment Videos
Heparin-binding EGF-like growth factor (HB-EGF) and necrotizing enterocolitis
Jiexiong Feng1, Osama N El-Assal, Gail E Besner
1Department of Surgery, Children's Hospital and The Ohio State University College of Medicine and Public Health, Columbus, Ohio 43205, USA.
Seminars in Pediatric Surgery
|August 9, 2005
Summary
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) shows promise in treating necrotizing enterocolitis (NEC). Administering HB-EGF significantly reduced NEC incidence and improved survival rates in neonatal rat models.
Area of Science:
- Neonatology
- Gastroenterology
- Regenerative Medicine
Background:
- Necrotizing enterocolitis (NEC) is a severe intestinal disease affecting premature infants with high mortality.
- Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has demonstrated protective effects on intestinal epithelial cells (IEC) in vitro.
Purpose of the Study:
- To investigate the therapeutic potential of HB-EGF in preventing and treating NEC.
- To evaluate the efficacy of HB-EGF administration in a neonatal rat model of NEC.
Main Methods:
- Utilized an established neonatal rat pup model of NEC.
- Administered exogenous HB-EGF to assess its impact on NEC incidence, severity, survival rate, and survival time.
- Analyzed endogenous HB-EGF mRNA expression in human NEC patient specimens.
Main Results:
- HB-EGF administration reduced NEC incidence from 65% to 27.3% (P < 0.05) in rats.
- Histological injury scores decreased, survival rates increased from 25% to 63.6%, and survival time was extended.
- Endogenous HB-EGF mRNA levels were higher in normal intestinal tissues compared to NEC-affected tissues in human newborns.
Conclusions:
- Exogenous HB-EGF administration effectively mitigates intestinal injury and improves outcomes in a neonatal NEC model.
- Endogenous HB-EGF plays a role in intestinal repair and regeneration.
- HB-EGF presents a promising therapeutic candidate for future NEC treatment strategies.